Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis

[1] Haroche J(2017)Histiocytoses: emerging neoplasia behind inflammation Lancet Oncol. 18 e113-e125

[2] Emile JF(2016)Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages Blood 127 2672-2681

[3] Gadner H(2013)Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis Blood 121 5006-5014

[4] Badalian-Very G(2010)Recurrent BRAF mutations in Langerhans cell histiocytosis Blood 116 1919-1923

[5] Durham BH(2016)Histiocytic neoplasms in the era of personalized genomic medicine Curr. Opin. Hematol. 23 416-425

[6] Diamond EL(2017)Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH Blood Advances 1 352-356

[7] Abdel-Wahab O(2014)Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Nat. Med. 20 430-435

[8] Kolenová Alexandra(2013)Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer J. Clin. Pathol. 66 381-385

[9] Schwentner Raphaela(2017)Integrating liquid biopsies into the management of cancer Nature Reviews Clinical Oncology 14 531-548

[10] Jug Gunhild(2017)Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults Blood 130 167-175

[1] Haroche J(2017)Histiocytoses: emerging neoplasia behind inflammation Lancet Oncol. 18 e113-e125

[2] Emile JF(2016)Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages Blood 127 2672-2681

[3] Gadner H(2013)Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis Blood 121 5006-5014

[4] Badalian-Very G(2010)Recurrent BRAF mutations in Langerhans cell histiocytosis Blood 116 1919-1923

[5] Durham BH(2016)Histiocytic neoplasms in the era of personalized genomic medicine Curr. Opin. Hematol. 23 416-425

[6] Diamond EL(2017)Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH Blood Advances 1 352-356

[7] Abdel-Wahab O(2014)Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Nat. Med. 20 430-435

[8] Kolenová Alexandra(2013)Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer J. Clin. Pathol. 66 381-385

[9] Schwentner Raphaela(2017)Integrating liquid biopsies into the management of cancer Nature Reviews Clinical Oncology 14 531-548

[10] Jug Gunhild(2017)Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults Blood 130 167-175